Bronchodilator response in bronchiectasis: mind the gap between definition and clinical reality Authors: Kang Li Published: 2026 Dear Editor, I read with keen interest the article by Kang et al. (1). The authors demonstrate that bronchodilator response (BDR) is associated with poorer lung function, more frequent exacerbations, and increased disease severity, advancing our understanding of BDR in bronchiectasis. However, I wish to offer several methodological considerations that could refine interpretation of their findings and guide future research. A fundamental concern pertains to the potential confounding effect of concurrent bronchodilator use on BDR assessment. The authors note that patients with BDR more frequently used inhaled corticosteroids combined with long-acting bronchodilators [long-acting beta-agonist (LABA)/long-acting muscarinic antagonist (LAMA)]. What remains unclear is whether these long-acting agents were appropriately withheld prior to spirometry. Current standardization guidelines recommend withdrawing long-acting bronchodilators for 24–48 hours before testing to avoid blunting the acute response to short-acting β2-agonists (2). If such withholding was not systematically ensured, the reported 7.3% BDR prevalence may substantially underestimate true airway reversibility in this cohort. Misclassifying patients with reversible airflow limitation as BDR-negative would directly attenuate the observed associations between BDR and clinical outcomes, potentially masking an even stronger relationship with disease severity than the authors reported. The concern is particularly salient given that concomitant LABA/inhaled corticosteroid (ICS) use is common in bronchiectasis populations (3). Future studies should mandate explicit reporting of medication withholding protocols. Beyond this, we propose a more informative approach: prospectively correlating acute BDR status with long-term symptomatic response to bronchodilator therapy. This would involve systematically documenting patient-reported outcomes, exacerbation rates, and quality-of-life measures following initiation of long-acting bronchodilators (4). Such an approach would distinguish pharmacological reversibility from sustained clinical benefit, clarifying whether acute BDR serves as a meaningful predictor of treatment response or merely represents an epiphenomenon of underlying disease severity. Second, the study relies exclusively on conventional spirometric indices [forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC)] to characterize lung function and define BDR, yet small airway dysfunction is increasingly recognized as a key pathological feature in bronchiectasis (5). Emerging evidence suggests that small airway obstruction may represent an initiating event in the disease cascade, contributing to air trapping, dyspnea, and exacerbation risk (5). By focusing solely on FEV1 and FVC, the current analysis may have overlooked a substantial proportion of patients whose functional impairment and bronchodilator responsiveness reside primarily in the peripheral airways. This is not a trivial omission: studies have demonstrated that impulse oscillometry parameters such as the difference between resistance at 5 and 20 Hz (R5–R20) can predict airway reversibility in bronchiectasis with an area under the curve of 0.794 (6). More fundamentally, a multidimensional approach to lung function assessment is essential, as factor analysis has revealed that airflow obstruction, dyspnea, and lung hyperinflation represent independent dimensions in bronchiectasis, with dyspnea correlating more closely with hyperinflation indices than with FEV1 (7). Future studies should therefore incorporate comprehensive physiological assessments that include impulse oscillometry parameters (R5, R5–R20, X5, AX) and plethysmographic measures of lung volumes (8). This would serve two purposes: (I) to determine whether BDR discordance between central and peripheral airways carries distinct prognostic implications; and (II) to identify patients who might derive symptomatic benefit from bronchodilators despite lacking conventional FEV1-based reversibility. Such an approach would align with the evolving paradigm of treatable traits in bronchiectasis, moving beyond a one size fits all definition of BDR toward a more nuanced understanding of how different compartments of the lung respond to pharmacological intervention. Third, the study defines BDR according to the 2005 ERS/ATS criteria (≥200 mL and ≥12% improvement) without testing the robustness of its findings to alternative definitions. The 2022 European Respiratory Society/American Thoracic Society (ERS/ATS) interpretive strategies introduced a revised threshold of >10% of the predicted value, a change intended to minimize sex- and height-related biases and align with the 95th percentile of response in healthy populations (7). By adhering exclusively to the 2005 definition, the current analysis may have misclassified a meaningful subset of patients. Recent multicenter evidence demonstrates that 12.3% of individuals initially classified as bronchodilator responders under the 2005 criteria are reclassified as non-responders when the 2022 criteria are applied (4). In the context of bronchiectasis, where comorbid asthma and chronic obstructive pulmonary disease (COPD) are prevalent, such reclassification is not trivial. Applying sensitivity analyses with both definitions to the KMBARC cohort would serve two critical purposes. (I) It would determine whether the observed associations between BDR and disease severity, exacerbation rates, and lung function impairment remain robust across criteria. (II) It would directly inform the field by clarifying whether the 2022 criteria offer superior prognostic discrimination in bronchiectasis populations. Such evidence would not only strengthen future iterations of bronchiectasis guidelines but also help clinicians better identify patients most likely to benefit from targeted therapeutic interventions. In summary, we commend Kang and colleagues for advancing our understanding of BDR in bronchiectasis. Addressing the methodological points outlined above, standardizing medication withdrawal before testing, integrating small airway function assessment, and performing sensitivity analyses with updated BDR criteria, would strengthen future investigations and help establish BDR not merely as a marker of disease severity, but as a clinically actionable tool guiding personalized therapeutic decisions. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Provenance and Peer Review: This article was a standard submission to the journal. The article did not undergo external peer review. Funding: This work was supported by the Yueyang Basic Research Program (No. 2025102400029). Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0952/coif). The author has no conflicts of interest to declare. References Associated Data Supplementary Materials The article’s supplementary files as